Literature DB >> 22658901

Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.

Fu-Shi Quan1, Min-Chul Kim, Byeong-Jae Lee, Jae-Min Song, Richard W Compans, Sang-Moo Kang.   

Abstract

Influenza virus like particles (VLPs) containing hemagglutinin were previously demonstrated to induce protection against the homologous strains. However, little information is available on the protective role of neuraminidase (NA), the second major glycoprotein. In this study, we developed VLPs (NA VLPs) containing NA and M1 derived from A/PR/8/34 (H1N1) influenza virus, and investigated their ability to induce protective immunity. Intranasal immunization with NA VLPs induced serum antibody responses to H1N1 and H3N2 influenza A viruses as well as significant neuraminidase inhibition activity. Importantly, mice immunized with NA VLPs were 100% protected against lethal infection by the homologous A/PR/8/34 (H1N1) as well as heterosubtypic A/Philippines/82 (H3N2) virus, although body weight loss was observed after lethal challenge with heterosubtypic H3N2 virus. The present study therefore provides evidence that influenza VLPs containing M1 and NA are capable of inducing immunity to homologous as well as antigenically distinct influenza A virus strains.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658901      PMCID: PMC5555301          DOI: 10.1016/j.virol.2012.05.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  60 in total

Review 1.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

2.  Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.

Authors:  B E Johansson; T M Moran; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

4.  Reactions of antibodies with surface antigens of influenza virus.

Authors:  R G Webster; W G Laver; E D Kilbourne
Journal:  J Gen Virol       Date:  1968-12       Impact factor: 3.891

5.  Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.

Authors:  Peter Pushko; Terrence M Tumpey; Neal Van Hoeven; Jessica A Belser; Robin Robinson; Margret Nathan; Gale Smith; D Craig Wright; Rick A Bright
Journal:  Vaccine       Date:  2007-03-09       Impact factor: 3.641

6.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

7.  Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.

Authors:  B E Johansson; J T Matthews; E D Kilbourne
Journal:  Vaccine       Date:  1998 May-Jun       Impact factor: 3.641

Review 8.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

9.  T cell regulation of immunoglobulin class expression in the antibody response to trinitrophenyl-ficoll. Evidence for T cell enhancement of the immunoglobulin class switch.

Authors:  P K Mongini; W E Paul; E S Metcalf
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

10.  Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs.

Authors:  Jodi McGill; Nico Van Rooijen; Kevin L Legge
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

View more
  33 in total

Review 1.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

2.  Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Authors:  Min-Chul Kim; Yu-Na Lee; Eun-Ju Ko; Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Jae-Min Song; Byung-Min Song; Youn-Jeong Lee; Jun-Gu Choi; Hyun-Mi Kang; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

3.  Identification of Conserved Peptides Comprising Multiple T Cell Epitopes of Matrix 1 Protein in H1N1 Influenza Virus.

Authors:  Neha Lohia; Manoj Baranwal
Journal:  Viral Immunol       Date:  2015-09-23       Impact factor: 2.257

4.  Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Authors:  Alaina J Mooney; Jon D Gabbard; Zhuo Li; Daniel A Dlugolenski; Scott K Johnson; Ralph A Tripp; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

5.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

6.  Mucosal adjuvants for influenza virus-like particle vaccine.

Authors:  Fu-Shi Quan; Eun-Ju Ko; Young-Man Kwon; Kyoung Hwan Joo; Richard W Compans; Sang-Moo Kang
Journal:  Viral Immunol       Date:  2013-11-16       Impact factor: 2.257

Review 7.  The prospects and challenges of universal vaccines for influenza.

Authors:  Kanta Subbarao; Yumiko Matsuoka
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

Review 8.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

9.  Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Authors:  Min-Chul Kim; Jong-Seok Lee; Young-Man Kwon; Eunju O; Youn-Jeong Lee; Jun-Gu Choi; Bao-Zhong Wang; Richard W Compans; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2013-06-27       Impact factor: 5.970

Review 10.  Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Authors:  Suzanne L Epstein
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.